SUMMARY
- Aikenist raised an undisclosed seed round backed by Venture Catalysts.
- The business offers AI-driven MRI solutions to enhance accessibility and diagnosis for critical illnesses like cancer and Alzheimer’s.
- Their flagship product, QuickSuite, streamlines radiology workflows with faster MRI scanning, interpretation, and data sharing.
Aikenist, an AI based health-tech firm, raised an undisclosed sum in a seed round backed by Venture Catalysts. Numerous prominent investors participated in the investment round, including angel investors, MARL Fund, Quant Fund, C-CAMP, Nandak Growth Catalysts, and others.
Aikenist, founded by Ashwin Amarapur, offers AI-accelerated magnetic resonance imaging (MRIs) to hospitals and diagnostic institutions. In order to make medical imaging more accessible to a wider audience for routine checkups of serious illnesses like cancer, Alzheimer’s disease, and common MSK issues, Aikenist seeks to provide cutting edge AI-based solutions for quicker MRI scanning, improved diagnosis capability, and turnaround time.
The company’s software as a service (SaaS) business model offers healthcare providers of all sizes flexibility through annual pricing or pay-per-use choices, ranging from small clinics to huge hospital networks.
QuickSuite, the flagship product of Aikenist, streamlines all radiology procedures, including scan acquisition, interpretation, and data reporting and sharing. The three components of the solution are QuickScan, a proprietary solution for faster MRI scanning, QuickRad, an AI-powered PACS & RIS system, and QuickDiag, which consists of specific suites for disease diagnosis and quantification.
